JP6783754B2 - 組織因子経路インヒビター（１〜１６１）上の２つのエピトープに結合する能力がある抗体 - Google Patents

組織因子経路インヒビター（１〜１６１）上の２つのエピトープに結合する能力がある抗体 Download PDF

Info

Publication number: JP6783754B2
Authority: JP; Japan
Prior art keywords: seq; tfpi; antibody; fab; mab
Prior art date: 2014-09-17
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Active

Application number

JP2017514888A

Other languages

English (en)

Japanese (ja)

Other versions

JP2017532313A (ja

JP2017532313A5 (2

Inventor

ヘレ・ハイブロク・ペーダセン

ビーリト・オールセン・クローウ

イェンス・ブラインホルト

ミケール・コフォーズ−ハンセン

イーダ・ヒルデン

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Novo Nordisk AS

Original Assignee

Novo Nordisk AS

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2014-09-17

Filing date

2015-09-17

Publication date

2020-11-11

2015-09-17 Application filed by Novo Nordisk AS filed Critical Novo Nordisk AS

2017-11-02 Publication of JP2017532313A publication Critical patent/JP2017532313A/ja

2018-10-04 Publication of JP2017532313A5 publication Critical patent/JP2017532313A5/ja

2020-11-11 Application granted granted Critical

2020-11-11 Publication of JP6783754B2 publication Critical patent/JP6783754B2/ja

Status Active legal-status Critical Current

2035-09-17 Anticipated expiration legal-status Critical

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/38—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against protease inhibitors of peptide structure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Immunology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Diabetes (AREA)
Hematology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Peptides Or Proteins (AREA)

JP2017514888A 2014-09-17 2015-09-17 組織因子経路インヒビター（１〜１６１）上の２つのエピトープに結合する能力がある抗体 Active JP6783754B2 (ja)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
EP14185138		2014-09-17
EP14185138.6		2014-09-17
PCT/EP2015/071359 WO2016042093A1 (en)	2014-09-17	2015-09-17	Antibodies capable of binding two epitopes on tissue factor pathway inhibitor (1-161)

Publications (3)

Publication Number	Publication Date
JP2017532313A JP2017532313A (ja)	2017-11-02
JP2017532313A5 JP2017532313A5 (2)	2018-10-04
JP6783754B2 true JP6783754B2 (ja)	2020-11-11

Family

ID=51542245

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP2017514888A Active JP6783754B2 (ja)	2014-09-17	2015-09-17	組織因子経路インヒビター（１〜１６１）上の２つのエピトープに結合する能力がある抗体

Country Status (6)

Country	Link
US (1)	US11279771B2 (2)
EP (1)	EP3194447B1 (2)
JP (1)	JP6783754B2 (2)
CN (1)	CN106687482B (2)
ES (1)	ES2905085T3 (2)
WO (1)	WO2016042093A1 (2)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US11566082B2 (en)	2014-11-17	2023-01-31	Cytiva Bioprocess R&D Ab	Mutated immunoglobulin-binding polypeptides
JP6983075B2 (ja)	2015-06-02	2021-12-17	ノヴォノルディスクアー／エス	極性の組換え延長部を有するインスリン
CN108136043B (zh)	2015-10-01	2022-09-06	诺和诺德股份有限公司	蛋白质缀合物
JP7031934B2 (ja)	2016-05-11	2022-03-08	サイティバ・バイオプロセス・アールアンドディ・アクチボラグ	分離マトリックス
JP6987424B2 (ja)	2016-05-11	2022-01-05	サイティバ・バイオプロセス・アールアンドディ・アクチボラグ	分離マトリックスを洗浄および／または消毒する方法
CN109071613A (zh)	2016-05-11	2018-12-21	通用电气医疗集团生物工艺研发股份公司	分离基质
US10730908B2 (en)	2016-05-11	2020-08-04	Ge Healthcare Bioprocess R&D Ab	Separation method
US10889615B2 (en)	2016-05-11	2021-01-12	Cytiva Bioprocess R&D Ab	Mutated immunoglobulin-binding polypeptides
US10703774B2 (en)	2016-09-30	2020-07-07	Ge Healthcare Bioprocess R&D Ab	Separation method
US10654887B2 (en)	2016-05-11	2020-05-19	Ge Healthcare Bio-Process R&D Ab	Separation matrix
US11708390B2 (en)	2016-05-11	2023-07-25	Cytiva Bioprocess R&D Ab	Method of storing a separation matrix
US12448411B2 (en)	2016-09-30	2025-10-21	Cytiva Bioprocess R&D Ab	Separation method
JP2020501561A (ja) *	2016-12-16	2020-01-23	ザ・ユニバーシティ・オブ・シドニー	脳卒中および関係する凝固性障害の処置のためのトロンビン阻害剤
CN110505885A (zh)	2017-04-05	2019-11-26	诺和诺德股份有限公司	寡聚体延伸的胰岛素-Fc缀合物
CN117285632A (zh) *	2022-06-17	2023-12-26	安源医药科技（上海）有限公司	针对tfpi的单克隆抗体及其用途

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2334107A1 (fr) *	1975-12-05	1977-07-01	Pasteur Institut	Procede de couplage de substances biologiques par des liaisons covalentes
US5589359A (en)	1994-08-05	1996-12-31	Chiron Corporation	Chimeric proteins
UA112050C2 (uk)	2008-08-04	2016-07-25	БАЄР ХЕЛСКЕР ЛЛСі	Терапевтична композиція, що містить моноклональне антитіло проти інгібітора шляху тканинного фактора (tfpi)
AU2014200227A1 (en)	2008-12-22	2014-01-30	Novo Nordisk A/S	Antibodies against tissue factor pathway inhibitor
WO2010072687A1 (en) *	2008-12-22	2010-07-01	Novo Nordisk A/S	Antibodies against tissue factor pathway inhibitor (tfpi)
EP2379600B2 (en) *	2008-12-22	2020-10-14	Novo Nordisk A/S	Antibodies against tissue factor pathway inhibitor
US8598327B2 (en)	2009-08-18	2013-12-03	Baxter International Inc.	Aptamers to tissue factor pathway inhibitor and their use as bleeding disorder therapeutics
JP2013533871A (ja) *	2010-06-30	2013-08-29	ノヴォノルディスクアー／エス	組織因子経路インヒビターに特異的に結合することが可能な抗体
PE20141149A1 (es) *	2011-04-01	2014-08-28	Bayer Healthcare Llc	Anticuerpos monoclonales frente al inhibidor de la ruta del factor tisular (tfpi)
WO2013141965A1 (en) *	2012-03-21	2013-09-26	Baxter International Inc.	Tfpi inhibitors and methods of use
EP2827910A2 (en)	2012-03-22	2015-01-28	Baxter International Inc	Aptamers to tissue factor pathway inhibitor and their use as bleeding disorder therapeutics
CN104185474B (zh)	2012-03-30	2017-08-25	拜尔健康护理有限责任公司	蛋白酶调节的抗体
US10457743B2 (en) *	2013-07-19	2019-10-29	Novo Nordisk A/S	Antibodies recognizing the N-terminal part of tissue factor pathway inhibitor capable of eliciting pro-coagulant activity

2015
- 2015-09-17 CN CN201580050660.3A patent/CN106687482B/zh active Active
- 2015-09-17 JP JP2017514888A patent/JP6783754B2/ja active Active
- 2015-09-17 EP EP15763621.8A patent/EP3194447B1/en active Active
- 2015-09-17 US US15/508,229 patent/US11279771B2/en active Active
- 2015-09-17 WO PCT/EP2015/071359 patent/WO2016042093A1/en not_active Ceased
- 2015-09-17 ES ES15763621T patent/ES2905085T3/es active Active

Also Published As

Publication number	Publication date
CN106687482B (zh)	2022-01-25
CN106687482A (zh)	2017-05-17
EP3194447A1 (en)	2017-07-26
EP3194447B1 (en)	2021-12-01
JP2017532313A (ja)	2017-11-02
US11279771B2 (en)	2022-03-22
WO2016042093A1 (en)	2016-03-24
ES2905085T3 (es)	2022-04-07
US20170260289A1 (en)	2017-09-14

Legal Events

Date	Code	Title	Description
2018-08-27	A521	Request for written amendment filed	Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180827
2018-08-27	A621	Written request for application examination	Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20180827
2019-08-09	A131	Notification of reasons for refusal	Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20190809
2019-11-11	A521	Request for written amendment filed	Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20191111
2020-03-23	A02	Decision of refusal	Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20200323
2020-07-16	A521	Request for written amendment filed	Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200716
2020-07-29	A911	Transfer to examiner for re-examination before appeal (zenchi)	Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20200728
2020-09-23	TRDD	Decision of grant or rejection written
2020-09-28	A01	Written decision to grant a patent or to grant a registration (utility model)	Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20200928
2020-10-26	A61	First payment of annual fees (during grant procedure)	Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20201022
2020-10-26	R150	Certificate of patent or registration of utility model	Ref document number: 6783754 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150
2023-09-28	R250	Receipt of annual fees	Free format text: JAPANESE INTERMEDIATE CODE: R250
2024-10-04	R250	Receipt of annual fees	Free format text: JAPANESE INTERMEDIATE CODE: R250

Publication	Publication Date	Title
JP6783754B2 (ja)	2020-11-11	組織因子経路インヒビター（１〜１６１）上の２つのエピトープに結合する能力がある抗体
CN105209497B (zh)	2021-09-07	能够特异性结合组织因子途径抑制物上的两个表位的抗体
CA2745317C (en)	2019-03-05	Antibodies against tissue factor pathway inhibitor
US20160297892A1 (en)	2016-10-13	Novel Methods and Antibodies for Treating Coagulapathy
JP2020115863A (ja)	2020-08-06	改良された血液凝固促進抗体
CN105473619B (zh)	2020-12-15	能够引起促凝血活性的识别组织因子途径抑制剂的n-末端部分的抗体
AU2014200227A1 (en)	2014-01-30	Antibodies against tissue factor pathway inhibitor